Comparative effectiveness research and personalized medicine: Catalyzing or colliding?

PharmacoEconomics

Volumn 28, Issue 10, 2010, Pages 905-913

  Epstein, Robert S ^a   Teagarden, J Russell ^a  

^a Medco Health Solutions   (United States)

Author keywords

clinical genetics; decision making; formularies; treatment outcome

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; WARFARIN;

ACUTE CORONARY SYNDROME; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLEEDING; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; CONFLICT; DECISION SUPPORT SYSTEM; DRUG INDUSTRY; DRUG USE; GENOTYPE; HEALTH CARE FINANCING; HEALTH CARE POLICY; HUMAN; MEDICAL INFORMATION SYSTEM; OUTCOMES RESEARCH; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW;

COMPARATIVE EFFECTIVENESS RESEARCH; EVIDENCE-BASED MEDICINE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INDIVIDUALIZED MEDICINE; OUTCOME ASSESSMENT (HEALTH CARE); TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES;

EID: 77956550527     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11535830-000000000-00000     Document Type: Review

References (39)

1. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003 Sep; 290: 1624-1632
2. Garber AM, Tunis SR. Does comparative-effectiveness re-search threaten personalized medicine? N Engl J Med 2009; 360: 1927-1929
3. Gibbons RJ, Gardner TJ, Anderson JL, et al., on behalf of the American Heart Association Advocacy Coordinating Committee. The American Heart Association's principles for comparative effectiveness research. Circulation 2009; 119: 2955-2962
4. Luce BR, Kramer JM, Goodman SN, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med 2009; 151: 206-209
5. Khoury MJ, Rich EC, Randhawa G, et al. Comparative effectiveness research and genomic medicine: an evolving partnership for 21st century medicine. Genet Med 2009 Oct; 11: 707-711
6. Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med 2009; 151: 203-205
7. Woodcock J. The human genome and translational re-search: how much evidence is enough? Health Aff (Millwood) 2008 Nov/Dec; 27: 1616-1618
8. Budnitz DS, Pollock DA, Weidenbach KN, et al. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006; 296: 1858-1866
9. Budniz DS, Shehab N, Kegler SR, et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007; 147: 755-765
10. Wadelius M, Chen LY, Downes K, et al. Common VKORCI and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5: 262-270
11. Bodin L, Verstuyft C, Tregouet D-A, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005 Jul; 106: 135-140
12. Gage BF, Johnson JA, Deych E, et al. Use of pharmacoge-netic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008 Sep; 84: 326-331
13. Caraco Y, Blotnick S, Muszkat M. CYP2C9 gentoype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008 Mar; 83: 460-470
14. Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2008 Feb; 83: 312-321
15. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002 Apr; 287: 1690-1698
16. Lima MV, Ribeiro GS, Mesquita ET, et al. CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur J Clin Pharmacol 2008 Jan; 64: 9-15
17. Ngow H, The LK, Langmia IM, et al. Role of pharmaco-diagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: a 6-month follow up study. Xenobiotica 2008; 38: 641-651
18. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 2005 Apr; 93: 700-705
19. Joffe HV, Xu R, Johnson FB, et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004 Jun; 91: 1123-1128
20. Garcia DA, Witt DM, Hylek E, et al. Delivery of optimized anticoagulant therapy: consensus statement from the An-ticoagulation Forum. Ann Pharmacother 2008 Jul/Aug; 42: 979-988
21. Ansell J, Hirsh J, Hylek E. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest 2008; 133 (6 Suppl.): 160S-98S
22. California Technology Assessment Forum. Use of genetic testing to guide the initiation of warfarin therapy: a technology assessment. San Francisco (CA): California Technology Assessment Forum, 2008 Mar 5
23. Flockhart DA, O'Kane D, Williams MS, et al. Pharmaco-genetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008 Feb; 10: 139-150
24. Aetna. Clinical policy bulletin: pharmacogenetic testing [online]. Available from URL: http://www.aetna.com/cpb/medical/data/700-799/0715.html [Accessed 2010 Jun 10].
25. Department of Health and Human Services, Centers for Medicare and Medicaid Services. Pharmacogenomic testing for warfarin response [Pub 100-103 Medicare national coverage determinations; online]. Available from URL: http://www.cms.hhs.gov/Transmittals/Downloads/R111NCD.pdf [Accessed 2010 Jun 10]
26. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116 (22): 2563-2570
27. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008; 83 (3): 460-470
28. Schwartz UI, Ritchie MD, Bradford Y, et al. Genetic de-terminants of response to warfarin during initial antic-oagulation. N Engl J Med 2008; 358 (10): 999-1008
29. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin geno-typing reduces hospitalization rates: results from the MM-WES (Medco-Mayo Warfarin Effectiveness) study. J Am Coll Cardiol. Epub 2010 Apr 7
30. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896
31. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247
32. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362
33. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-857
34. US Department of Health and Human Services; US FDA. Plavix (clopidogrel): reduced effectiveness in patients who are poor metabolizers of the drug [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm 204256.htm [Accessed 2010 Jun 10].
35. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel ver-sus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015
36. Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major east Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol. Epub 2010 Feb 19
37. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41 (12): 913-958
38. Hudson K. The health benefits of genomics: out with the old, in with the new. Health Aff (Millwood) 2008 Nov/Dec; 27: 1612-1615
39. Woodcock J, Lesko LJ. Pharmacogenetics: tailoring treat-ment for the outliers. N Engl J Med 2009; 360: 811-3